Aprameya Engineering Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book

Q4 FY25 earnings call analysis: revenue, margin, capex, fundraise and order book outlook from management commentary.

Published 16 Jul 2026 | Healthcare Equipment & Supplies | Market Cap: ₹266 Cr

Aprameya aims to achieve sustained growth faster than the healthcare infrastructure industry's CAGR of 22% over the last decade. Aprameya aims to sustain strong growth, leveraging proprietary turnkey projects and expanding services.

From Aprameya Engineering Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.

Price

₹139

Market Cap

₹266 Cr

P/E Ratio

52.8

How does Aprameya Engineering Ltd rank in Healthcare Equipment & Supplies?

Compare Aprameya Engineering Ltd against every Healthcare Equipment & Supplies company this quarter on revenue, margins and earnings-call signals.

Revenue: Rank 3Margin: Rank 3

View Healthcare Equipment & Supplies leaderboard →

📊 Revenue & Sales Performance

Rank 3

→Aprameya aims to achieve sustained growth faster than the healthcare infrastructure industry's CAGR of 22% over the last decade.
→The company is optimistic about securing good orders across multiple states due to its proprietary products and strong entry barriers in tenders.
→With an expanding geographic footprint into states like Bihar, Uttarakhand, Assam, Chhattisgarh, Daman, and Sikkim, Aprameya is positioned for scalable growth.
→Order book stood at INR 60 crores, with expectations for continuous order inflow driven by unique, lifesaving proprietary solutions.
→Revenue grew by 108% YoY to INR 136 crores in FY25, backed by a higher share of high-margin turnkey projects.
→Management expresses confidence in maintaining and improving margins and increasing service contracts, which contribute recurring revenue.
→Future guidance hints at steady revenue growth, though no specific growth percentage is promised.

📈 Profitability & Margins

Rank 3

→Aprameya aims to sustain strong growth, leveraging proprietary turnkey projects and expanding services.
→The company is confident in maintaining current margin levels, focusing on high-margin projects and selective bidding.
→EBITDA margin improved to 18% in FY25; this level is expected to be sustainable with disciplined cost and capital management.
→PAT margin increased to 12% in FY25, reflecting operational efficiencies.
→Growth driven by geographic expansion into underpenetrated states like Bihar, Assam, and Uttarakhand.
→Expanding order book with INR60 crores executing over 5-6 months and targeting high-margin contracts.
→Focus on increasing services and CMC contracts post three-year warranty completion, which have higher margins.
→Entering specialized proprietary product markets (e.g., EP lab systems) to boost margins and revenues.
→Cash flow improvements expected due to reducing debtor cycles.
→Management confident in delivering sustained earnings growth but cautious on aggressive margin guidance without contract clarity.

See what Aprameya Engineering Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

Yes

→Capex for expansion into new states will be gradual, not a one-time large investment; focus is on brownfield projects (working inside existing buildings) rather than greenfield projects.
→Capital investments in new states will be phased over 2-3 months per project rather than upfront heavy capital.
→The company plans to control capex carefully to avoid hampering cash flow and maintain a balanced inflow and outflow ratio.
→Specific capex figures are not shared publicly; investors are encouraged to contact the IR agency for detailed queries.
→Debt levels have been declining year-on-year, and the company aims to manage working capital efficiently during expansion to avoid raising significant new debt.
→Expansion will be selective, focusing only on projects where margins, revenue, and credit terms are comfortable to secure.

💰 Fundraising & Capital Structure

Yes

→The management did not mention any specific plans for raising new debt or equity during the expansion.
→They emphasized reducing the debtor cycle to improve cash flow and funding projects "as per our requirement only."
→Capex for expansion will be gradual and aligned with cash inflows from ongoing projects, not requiring large upfront investments.
→For exact capex figures or potential fundraising details, the management directed investors to contact their IR agency, Stellar, for specific queries.
→The company aims to maintain manageable debt levels and has been successfully reducing net debt year-on-year.
→Overall, the approach is cautious, focusing on operational cash flow and selective project bidding without immediate plans to raise significant external funds.

See what Aprameya Engineering Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

Yes

→Current order book: Approximately INR 60 crores.
→Execution timeline: Orders expected to be completed within 5 to 6 months.
→Geographic split: 60%-70% from Maharashtra, 10%-20% from Rajasthan, remaining from Gujarat.
→Growth outlook: Company optimistic about securing additional orders due to sector growth and strong entry barriers.
→Previous projects and order pipeline suggest sustained opportunities for expansion across multiple states.
→The company expects to maintain steady order inflow aligned with industry CAGR growth trends.

Key Metrics

3 of 5 growth signals positive in the Q4 FY25 call.

Revenue

Rank 3

Margin

Rank 3

Capex

Yes

Fundraise

Yes

Order Book

Yes

How does Aprameya Engineering Ltd rank vs peers in Healthcare Equipment & Supplies?

Pro feature

1Aprameya Engineering Ltd

Rev 3Mar 3

See full Healthcare Equipment & Supplies sector rankings

Others in Healthcare Equipment & Supplies this season

MADHAVBAUG (Q4 FY25)
120 crores. Key concall takeaways from Vaidya Sane Ayurved Laboratories Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
POLYMED (Q4 FY25)
EBITDA margins guided between 25%-27%, with potential upside if export growth exceeds 15%. Key concall takeaways from Poly Medicure Ltd's Q4 FY25 earnings call…
OSEL Devices Ltd (Q4 FY25)
Current order-in-hand for OSEL Devices Limited is approximately INR 40-45 crores. Key concall takeaways from OSEL Devices Ltd's Q4 FY25 earnings call — and how…
PREVEST (Q4 FY25)
The management emphasizes growth in both domestic and export markets, indicating healthy order inflows aligned with a 13% sales increase in FY25. Key concall…

Compare:vs POLYMED vs MOLBIO vs Fischer Medical Ventures Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Aprameya Engineering Ltd Q4 FY25 results?

What is Aprameya Engineering Ltd share price analysis?

Aprameya Engineering Ltd currently shows a below-average growth signal. The stock trades at a P/E of 52.8 with a market cap of ₹266 Cr. Investors should review the full earnings analysis for detailed insights.

Is Aprameya Engineering Ltd planning capital expenditure?

Capex for expansion into new states will be gradual, not a one-time large investment; focus is on brownfield projects (working inside existing buildings) rather than greenfield projects.

Keep Aprameya Engineering Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.

How does Aprameya Engineering Ltd rank in Healthcare Equipment & Supplies?

📊 Revenue & Sales Performance

🏗️ Capital Expenditure Plans

📋 Order Book & Pipeline

Key Metrics

Continue your research

Others in Healthcare Equipment & Supplies this season

Frequently Asked Questions